| 3.11.1 Antifibrotics |
RED Pirfenidone capsules 267mg
|
For the treatment of idiopathic pulmonary fibrosis recommended as an option by NICE TA504 in adults only if:
|
| > the person has a forced vital capacity (FVC) between 50% and 80% predicted |
| > the company [provides pirfenidone with the agreed discount agreed in the patient access scheme and |
| > treatment is stopped if there is evidence of disease progression (an absolute decline of 10% or more in predicted |
| FVC within any 12-month period). |
| |
| NICE TAG379 Nintendanib (FVC between 50% and 80% predicted) |
RED Nintedanib capsules 100mg, 150mg
|
| For the treatment of idiopathic pulmonary fibrosis in people with a forced vital capacity (NICE TAG379) |
between 50% and 80% predicted recommend as an option by NICE.
|
| |
NICE TA864 Nintedanib (forced vital capacity above 80% predicted)
|
| RED Nintedanib (Ofev®) |
| Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis in adults, only if: |
| > they have a forced vital capacity of above 80% predicted |
| > the company provides it according to the commercial arrangement. |
| NHS England Commissioned |
| RED Nintedanib (Ovef®) |
| NICE TA747 Recommended, within its marketing authorisation, as an option for treating chronic progressive fibrosing |
interstitial lung diseases (PF‑ILD) in adults.
|
| NHS England Commissioned |
